Clinical Trial for Optimal Novel Oral Anticoagulant (NOAC) Schedule Immediate Before Catheter Ablation for Atrial Fibrillation

• Status: Unknown status
• Trial end date: 2019-06-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is to evaluated the interruption schedule of NOAC in patients who undergo atrial fibrillation ablation. The investigators will compare the bleeding complications were classified as major and minor bleeding, thromboembolic, vascular complications, Re-admission and increased in the length of hospital stay during the 30-day post-radiofrequency catheter ablation(RFCA) period among patients who interrupt NOAc 24hours before ablation and patients who stop NOAC in the morning of the procedure.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Yonsei University
• Treatments: Anticoagulants

Criteria

Inclusion Criteria:

1. Patients who consent with study

2. Patients with Atrial fibrillation (20-80 years old)

3. patients who undergoing catheter ablation of atrial fibrillation due to symptomatic, drug refractory atrial fibrillation

4. Patients possible to NOAC

Exclusion Criteria:

1. Patients who do not agree with study inclusion

2. eGRF < 30ml/min

3. Impossible to NOAC

4. Structural cardiac disease

5. Major hemorrhagic complication

6. CHA2DS2-VASc score > 5

7. Patients who have experienced Ischemic cerebellar infarction more than 2times